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follow-up for predicting cardiac events in adolescent Kawasaki disease (KD) patients with coronary artery lesions
(CALs).Background Although DSE is an established technique for the detection of coronary artery disease, its prognostic value to predict
cardiac events in adolescent KD patients with CALs is unknown.Methods Fifty-eight adolescent KD patients, including 36 patients with CALs documented by coronary angiography, and
22 patients with normal coronary arteries documented by echocardiography who underwent DSE were reviewed at
initial testing (mean age: 13.6 years) and at 15 years’ follow-up. Follow-up events were tabulated as major adverse
cardiac events (MACEs) that included cardiac death, nonfatal myocardial infarction, and revascularization.Results During a mean follow-up of 14.7 years, there were 16 patients with MACEs (acute myocardial infarction: n ¼ 1;
old myocardial infarction: n ¼ 7; coronary artery bypass grafting: n ¼ 4; percutaneous coronary intervention: n ¼ 4).
Signiﬁcant coronary artery disease (CAD) (>70% coronary stenosis) was detected in 31.0% of patients at initial
testing and 42.1% at follow-up. However, there were no signiﬁcant differences in wall motion score indices (WMSI)
at peak DSE between initial testing and follow-up (p ¼ 0.762). Five of 6 patients (85%) with false-positive DSE
results (WMSI: 1.25) at initial testing, who had giant aneurysms without CAD, developed CAD with MACEs during
follow-up. Cumulative event-free survival rate to 15 years was 25.0% in patients with WMSI 1.25 and 91.7% in
patients with WMSI <1.25. Cox regression analysis showed the grade of peak WMSI at initial testing to be the only
independent predictor of MACEs (relative risk: 3.28; 95% conﬁdence interval: 1.73 to 6.20).Conclusions DSE provided independent prognostic information up to 15 years in adolescent KD survivors. (J Am Coll Cardiol
2014;63:337–44) ª 2014 by the American College of Cardiology FoundationKawasaki disease (KD) is a systemic vasculitis of unknown
origin in young children. Although intravenous immuno-
globulin infusion initiated at the acute phase reduces the
morbidity of KD and the incidence of coronary artery lesions
(CALs) such as coronary artery ectasia or coronary aneurysm
(1,2), some patients still develop coronary aneurysms,
leading to coronary artery disease (CAD, i.e., coronary artery
stenosis or obstruction), which often induces myocardial
infarction and cardiac death during the convalescent stagend Child Health, Nihon University School of
s have reported that they have no relationships
to disclose.
3; revised manuscript received July 25, 2013,(3,4). The progression of a coronary aneurysm to a stenotic
lesion is an important determinant of the prognosis of KD
and CALs (5); however, little is known about the incidence
of coronary stenotic lesions during follow-up in KD patients
with CALs (6,7). Moreover, studies concerned with the
prediction of cardiac events, including cardiac death, acute
myocardial infarction (AMI), old myocardial infarction
(OMI), and revascularization in adolescents and young
adults with KD and CALs, have not been reported.
Dobutamine stress echocardiography (DSE) is a widely
accepted and useful noninvasive test for the diagnosis, risk
stratiﬁcation, and prognosis of adult patients with suspected
or known CAD (8,9). DSE has also been shown to provide
valuable information for the detection of coronary artery
stenosis in children and adolescents with KD (10). Although
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338DSE is an established technique
for the detection and prognostic
stratiﬁcation of CAD, the prog-
nostic value of DSE in adoles-
cents and young adults with KD
and CALs for predicting cardiac
events is unknown. This study
was designed to determine the
prognostic value of DSE in-
volving a 15-year follow-up for
predicting the cardiac events in
adolescents and young adults
with KD and CALs.Methods
Subjects. Consecutive KD pa-
tients meeting the following
criteria were recruited from our
outpatient clinic between August
1996 and August 1998: 1) a
diagnosis of KD; 2) an interval
from initial onset of illness of 5
years; 3) KD patients who re-
ceived periodic follow-up at our
institution; and 4) KD patients
who underwent DSE for the
detection of CALs during thattime period. In our institution, KD follow-up protocol
includes annual DSE beginning 5 years after the initial onset
of illness in patients with risk level IV (large or giant coronary
aneurysm) or V (coronary artery obstruction) and biennial
DSE in patients with risk level III (small-to-medium coro-
nary aneurysm). Patients with risk level I (no coronary artery
changes) or II (transitional coronary artery ectasia) undergo
DSE only when they have an episode of atypical chest pain,
resting electrocardiogram changes, and nondiagnostic or
ambiguous exercise stress electrocardiogram results according
to the risk stratiﬁcation of American Heart Association
guidelines (11). Subjects were excluded if they had a history
of any cardiac events including nonfatal myocardial infarction
and revascularization prior to 5 years from initial onset of
illness. The study was approved by the human research ethics
committee of our institution, and written informed consent
for participation in this study was obtained from all subjects
or their parents.
Follow-up and endpoints. Follow-up data, including
medical records, DSE results, details of major coronary
arteries by either quantitative coronary angiography (CAG)
or computed tomography coronary angiography (CTCA) in
KD patients with CALs and by two-dimensional echocar-
diography in KD patients without CALs, were reviewed
during initial testing (I) (from 1996 to 1998). To investigate
the incidence of CAD and the diagnostic accuracy of DSE
in KD patients over time, the same variables were compared
between (I) and at follow-up testing (F) (from 2010 to2012). A follow-up period of 15 years was used when
plotting survival curves. The endpoints were all-cause
mortality and major adverse cardiac events (MACEs).
MACEs, assessed individually and as a composite, were
nonfatal myocardial infarction, including AMI and OMI;
cardiac death; and revascularization. AMI was diagnosed in
patients with symptoms of myocardial ischemia accompa-
nied by an increase in a marker of myocardial necrosis. OMI
was diagnosed in patients who had no subjective symptoms
at the time when an abnormal Q-wave was observed on the
electrocardiogram. Cardiac death was documented as death
related to MI, congestive heart failure, sudden cardiac death,
or arrhythmia. Revascularization included any percutaneous
coronary intervention (PCI) or coronary artery bypass
grafting (CABG). In our institution, PCI was considered in
patients with ischemic symptoms, patients without ischemic
symptoms but ischemia on stress tests, and patients without
ischemia but with >75% stenosis in the left anterior
descending coronary artery that could potentially result in
sudden cardiac death. In addition, CABG was considered in
patients with ﬁndings of ischemia for which PCI is con-
traindicated, including patients with a severe occlusive lesion
of the left main coronary artery or left anterior descending
coronary artery, with severe multivessel occlusive lesions and
with jeopardized collateral according to the guidelines (12).
Dobutamine stress echocardiography protocol. Trans-
thoracic echocardiography was performed with a 2.5-MHz
or 3.75-MHz phased array transducer (model SSH 140A
or SSH 880A, Toshiba Medical Systems, Tokyo, Japan).
Images were obtained in standard parasternal long-axis and
short-axis, apical 4-chamber, and 2-chamber views at
baseline and after each incremental dose of dobutamine. An
infusion of dobutamine was started at 5 mg/kg/min and
increased every 3 min to 10, 20, 30, and 40 mg/kg/min until
the target heart rate was achieved. Dobutamine infusion was
terminated if the target heart rate (85% of the age-predicted
maximal heart rate) was achieved; the protocol was
completed; or for standard indications such as severe chest
pain, ST-segment depression >2 mm, marked hypertensive
response of >210 mm Hg systolic blood pressure, devel-
opment of new or worsening regional wall motion abnor-
malities (WMA), or if requested by patients. Images were
digitized and displayed in 4-quadrant views for side-by-side
comparison of baseline, 10-mg, peak dose, and recovery
images and stored on a magneto-optical disk for ofﬂine
analysis.
DSE analysis. A normal response to dobutamine infusion
was deﬁned as a progressive increase in myocardial thick-
ening and hyperdynamic wall motion from rest to peak dose
of dobutamine infusion (negative DSE). An abnormal
response to dobutamine infusion was deﬁned as a reduction
in myocardial thickening or wall motion at any stage of the
dobutamine infusion compared with the previous stage
(positive DSE). The wall motion of the left ventricle was
assessed with a 16-segment model, which was scored
according to a 4-point scale: 1 for normokinesia, 2 for
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339hypokinesia, 3 for akinesia, and 4 for dyskinesia. The overall
wall motion score was then calculated as the sum of scores in
visualized segments divided by the number of segments
visualized (13). The digitized images were independently
interpreted by 2 reviewers unaware of the history of and
angiographic ﬁndings in the patients. Discrepancies in the 2
reviewers’ interpretations were resolved by a third reviewer.
In our laboratory, the intraclass correlation coefﬁcient of wall
motion score assessed by the two reviewers was 0.95, and
only 3.1% of the interpretations required resolution by
a third reviewer. If a patient had more than 1 DSE during
that time period, only the ﬁrst test was entered into the
analysis.
Quantitative CAG and CTCA. Quantitative CAG or
CTCA was performed a few days after DSE. Locations of
the coronary aneurysms and stenosis were determined ac-
cording to American Heart Association reporting systems.
Quantitative angiographic measurements were performed
with an edge detection program. The percentage of coronary
stenosis was calculated with the nearest normal-appearing
portion of the coronary artery used as a standard. Signiﬁ-
cant CAD was deﬁned as a reduction in diameter of more
than 70% of at least 1 major coronary artery.
CTCA was performed using a 320-detector-row com-
puted tomography scanner (each 0.5 mm wide, Acquilion
One; Toshiba Medical Systems, Otawara, Japan). Meto-
prolol was administered orally (50 to 100 mg, depending on
heart rate [HR]) 1 h before data acquisition to patients with
an HR exceeding 65 beats/min, unless contraindicated. The
entire heart was imaged in a single beat, with a maximum of
16-cm craniocaudal coverage. The image acquisition
window was set at 65% to 85% of R-R interval in patients
with HR 60 beats/min and at 75% of R-R interval in
patients with HR <60 beats/min. Tube voltage was
approximately 80 to 120 kV. An injection of intravenous
contrast medium was administered, and the amount of
nonionic contrast medium (Iomeron 400, Bracco, Milan,
Italy) injected into the antecubital vein ranged from 60 to
80 ml (depending on the body weight). All images were
acquired during an inspiratory breathhold of w5 s. An
initial data set was reconstructed at an R-R interval of 75%,
with a slice thickness of 0.5 mm and a reconstruction
interval of 0.25 mm (14).
Statistical analysis. Descriptive analysis was performed by
comparing clinical and demographic variables between (I)
and (F). A paired t test was used for continuous variables,
and McNemar test was used for categorical variables.
Kaplan-Meier analysis was used to create event-free survival
curves for individual MACEs. The log-rank test was used for
comparison between the 2 groups. The Cox proportional
hazards regression model was used to evaluate clinical, de-
mographic, and stress echocardiography variables as pre-
dictors of MACEs. From the multivariable modeling,
adjusted hazard ratios with 95% conﬁdence intervals were
calculated, along with p values. Probability values<0.05 were
considered statistically signiﬁcant. All statistical analysis wasperformed using SPSS version 10.0 software (SPSS Inc.,
Chicago, Illinois).Results
Study population. Sixty-ﬁve post-KD patients were
screened for this study. Seven patients were excluded because
of a history of nonfatal MI in 5 patients and revasculariza-
tion in 2 patients. The remaining 58 KD patients (male:
68.9%; 7 to 18 years of age; mean: 13.6  4.4 years of age;
number of years since initial onset of illness ranging from 6
to 14 years: mean, 9.8  4.0 years), including 8 KD patients
who have been reported previously, were entered into this
study (10). Thirty-six of the 58 patients had persistent
CALs documented by previous CAG. Among them were 8
patients with left coronary aneurysm, 15 patients with right
coronary aneurysm, and 13 patients with bilateral coronary
aneurysms. As for the initial aneurysmal size, there were 16
patients with giant aneurysm (8 mm internal diameter),
9 patients with large aneurysm (6 to 8 mm internal
diameter), 6 patients with medium aneurysm (4 to 6 mm
internal diameter), and 5 patients with small aneurysms
(<4 mm internal diameter). Twenty-two of the 58 patients
had normal coronary arteries as documented by serial two-
dimensional echocardiography. No patient with a history
of transient coronary ectasia or regressed coronary aneurysm
was found in this patient cohort.
All KD patients with CALs were receiving medical
therapy; 14 were receiving aspirin only, and 18 were
receiving aspirin and warfarin for the prevention of coronary
thrombosis. Three patients were receiving calcium channel
blocker in addition to aspirin and warfarin, and 1 patient was
receiving both beta-blocker and calcium channel blocker in
addition to aspirin for the control of sustained ventricular
tachycardia.
Follow-up and cardiac events. Figure 1 shows the
outcome of KD patients with or without CALs during
follow-up. During a mean follow-up of 14.7  5.5 years),
there were 8 patients (13.7%) who underwent revasculari-
zation (CABG: n ¼ 4; PCI: n ¼ 4) and 8 patients (13.7%)
who had nonfatal MIs (AMI: n ¼ 1; OMI: n ¼ 7) among
the KD patients with CALs. No cardiac deaths had occurred
during follow-up. The average age upon cardiac events was
18.8  6.6 years (range: 6 to 26 years); however, there was
no tendency regarding the age of occurrence of cardiac
events in KD patients with CALs within the 15-year follow-
up (Table 1). Finally, the 38 survivors, including 20 KD
patients with CALs and 18 patients without CALs, were
reviewed for the follow-up testing during (F). Four addi-
tional KD patients without CALs were excluded because 1
or more components of the data in follow-up testing were
missing. There were no KD patients without CALs who
progressed from a normal appearing coronary artery to
CALs or CAD during follow-up.
Initial and follow-up data. Initial and follow-up data are
summarized in Table 2. Although there was no signiﬁcant
Figure 1 Outcome
Outcome of KD patients with or without CALs at initial testing and during follow-up. AMI ¼ acute myocardial infarction; CABG = coronary artery bypass grafting; CAD ¼ coronary
artery disease; CAL ¼ coronary artery lesion; KD ¼ Kawasaki disease; OMI ¼ old myocardial infarction; PCI = percutaneous coronary intervention.
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340difference in the incidence of CALs between (I) and (F), (I)
had a higher incidence of CALs with left coronary artery
(LCA) (22.2%) than (F) (5.0%), but the difference was not
signiﬁcant (p ¼ 0.092). In contrast, (F) (42.1%) had a higher
incidence of CAD than (I) (31.0%), despite the exclusion of
patients with MACEs at (F), but the difference was not
signiﬁcant (p ¼ 0.447). As for the variables of DSE, no KDTable 1 Proﬁle of Patients With Cardiac Events





1 PCI 1 15
2 OMI 4 18
3 PCI 2 20
4 OMI 2 17
5 AMI 9 18
6 PCI 1 24
7 OMI 1 21
8 OMI 3 18
9 CABG 1 13
10 CABG 1 6
11 PCI 0.8 14
12 OMI 2 20
13 CABG 0.6 6
14 CABG 1 16
15 OMI 2 26
16 OMI 5 20
AMI ¼ acute myocardial infarction; AN ¼ aneurysm; CABG ¼ coronary artery bypass grafting; CAL ¼ coro
coronary intervention; RCA ¼ right coronary artery; WMSI ¼ wall motion score index.patient exhibited resting wall motion abnormality by DSE at
either (I) or (F). No signiﬁcant differences were observed
in the positivity of DSE between (I) and (F) (p ¼ 0.837).
With regard to WMA by DSE corresponding to the
distribution of CAD, there were no signiﬁcant differences in
the incidence of homozonal positivity (WMA belonging




CALs (% of Stenosis)
(Initial/Events)
1.250 LCA (giant AN 50%/90%)
1.250 RCA (giant AN 90%/100%)
1.250 LCA (50%/90%)
1.250 RCA (giant AN 0%/99%)
1.375 LCA (75%/90%) RCA (giant AN 0%/100%)
1.310 LCA (giant AN 50%/90%)
1.250 RCA (90%/100%)
1.250 LCA (75%/90%) RCA (giant AN 0%/100%)
1.375 LCA (75%/90%)
1.375 LCA (75%/99%)
1.375 LCA (25%/90%) RCA (90%/100%)
1.250 RCA (90%/100%)
1.500 LCA (giant AN 50%/100%)
1.375 LCA (75%/100%)
1.250 RCA (90%/100%)
1.250 RCA (giant AN 0%/100%)
nary artery lesion; LCA ¼ left coronary artery; OMI ¼ old myocardial infarction; PCI ¼ percutaneous





(n ¼ 38) p Value
Age (yrs) 13.6  4.4 23.8  7.3 <0.001
Male 40/58 (68.9%) 24/38 (63.1%) 0.791
CALs 36/58 (62.0%) 20/38 (52.6%) 0.635
LCA 8/36 (22.2%) 1/20 (5.0%) 0.092
RCA 15/36 (41.6%) 9/20 (45.0%) 0.809
Bilateral 13/36 (36.1%) 10/20 (50.0%) 0.311
CAD 18/58 (31.0%) 16/38 (42.1%) 0.447
Maximal dose of DOB,
mg/kg/min
23.3  4.1 24.2  3.5 0.264
DSE positive 24/58 (41.3%) 17/38 (44.7%) 0.837
homozonal 17/24 (70.8%) 16/17 (94.1%) 0.545
heterozonal 7/24 (29.2%) 1/17 (5.9%) 0.121
DSE sensitivity 94.4% 93.7% 0.988
DSE speciﬁcity 82.5% 95.4% 0.704
WMSI at peak 1.17  0.15 1.18  0.17 0.762
Values are mean  SD, n/N (%), or %.
CAD ¼ coronary artery disease; CALs ¼ coronary artery lesions; DOB ¼ dobutamine;
DSE ¼ dobutamine stress echocardiography; LCA ¼ left coronary artery; RCA ¼ right coronary
artery; WMSI ¼ wall motion score index.
Figure 2 Cardiac Event-Free Survival in KD Patients
Kaplan-Meier curves for cardiac event-free survival in KD patients with negative
DSE and positive DSE (log-rank test, p ¼ 0.010). DSE ¼ dobutamine stress
echocardiography; KD ¼ Kawasaki disease.
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341(p ¼ 0.545). The incidence of heterozonal positivity (WMA
remote from the distribution territory of CAD) at (I)
(29.2%) was higher than that at (F) (5.9%), but this differ-
ence did not reach statistical signiﬁcance (p ¼ 0.121). Thus,
the sensitivity and speciﬁcity of DSE results for the detec-
tion of CAD were 94.4 and 82.5% at (I) and 93.7 and 95.4%
at (F), respectively. Meanwhile, no signiﬁcant difference was
observed in wall motion score index (WMSI) at peak stress
by DSE between (I) and (F) (1.17  0.15 vs. 1.18  0.14,
respectively). Five of 6 patients (85%) with false-positive
DSE (WMSI: 1.25) at (I) who all had giant aneurysms
(8 mm) without CAD developed signiﬁcant CAD with
cardiac events during follow-up.
Kaplan-Meier analysis for event-free survival showed a
better outcome for KD patients with negative DSE than for
those with positive DSE (25.3% vs 87.5%; p ¼ 0.010)
(Fig. 2). When we divided peak WMSI into 5 grades based
on the difference of 1 SD (0.125) in our data of WMSI
at (I) (grade 1 is 1.0 to 1.125; grade 2 is 1.125 to
1.25>; grade 3 is 1.25 to 1.375; grade 4 is 1.375 to 1.5;
and grade 5 is 1.5), cumulative event-free survival to 15
years was 25.0% in patients with WMSI  1.25 and 91.7%
in patients with WMSI <1.25 (p < 0.001) (Fig. 3). When
we also categorized the initial aneurysmal size into 4 types
(giant aneurysm: 8 mm; large aneurysm: 6 to 8 mm;
medium aneurysm: 4 to 6 mm; and small aneurysm:
<4 mm), cumulative event-free survival rates to 15 years
were 13.9% in patients with large to giant aneurysms
(6 mm) and 74.2% in patients with small to medium
aneurysms (<6 mm) (p ¼ 0.012) (Fig. 4). Five variables
were identiﬁed as univariate predictors of MACEs: existence
of giant aneurysms (8 mm) (p ¼ 0.039), positive DSE
(p ¼ 0.035), existence of large to giant aneurysms (6 mm)
(p ¼ 0.021), percent stenosis (LCA) (p ¼ 0.005), and gradeof WMSI at peak stress (p < 0.001) (Table 3). Cox
regression analysis showed the grade of WMSI at peak stress
(1 to 5) at (I) to be the only independent predictor of future
MACE (relative risk: 3.37; 95% conﬁdence interval: 1.29 to
8.84; p ¼ 0.013).Discussion
This study demonstrated that the degree of wall motion
abnormalities induced by DSE provided risk stratiﬁcation
and independent prognostic information associated with
MACEs up to 15 years after initial testing in patients with
KD and CALs. To the best of our knowledge, this is the
ﬁrst study of the prediction of future MACEs in adolescents
and young adults with KD and CALs.
The morphological changes of aneurysms in the course of
follow-up depend on the initial coronary artery diameter in
the acute phase of KD (7). It is generally accepted that an
initial aneurysm exceeding 8.0 mm (giant aneurysm) evolves
into CAD (15). Moreover, it was shown that KD patients
with an initial coronary aneurysm exceeding 6.0 mm (large
aneurysm) had a greater than 50% chance of developing
a clinically signiﬁcant stenotic coronary artery during
a follow-up of 15 years (7). In fact, we also found the
progression of CALs to CAD over time in KD patients with
large to giant aneurysm in this study. CAD is the most
important coronary arterial lesion caused by KD because it
induces myocardial ischemia and MI, which inﬂuence the
prognosis. Recently, the clinical features of 50 adult KD
patients (mean age: 28 years old) who had an acute coro-
nary syndrome caused by CALs were revealed. Of these
50 patients, 43 (86%) had thrombotic occlusion of an
Figure 3 Cardiac Event-Free Survival in KD Patients With WMSI
Kaplan-Meier curves for cardiac event-free survival in KD patients with WMSI divided into 5 grades (log-rank test, p < 0.001). WMSI grade 1 ¼ 1.0 to 1.125>;
grade 2 ¼ 1.125 to 1.25; grade 3 ¼ 1.25 to 1.375; grade 4 ¼ 1.375 to 1.5; grade 5 ¼ 1.5. KD ¼ Kawasaki disease; WMSI ¼ wall motion score index.
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342aneurysm and 40 (80%) had giant coronary aneurysms. In
contrast, late mortality and morbidity from coronary disease
in patients who had small persistent or regressed aneurysms
have not been reported (16). On the basis of this accumu-
lating evidence, it is likely that patients with known severe
coronary aneurysms during the acute phase of KD will have
some cardiovascular morbidity and mortality as young adults
(17). However, it is questionable whether the level of initialFigure 4 Cardiac Event-Free Survival in KD Patients Divided by Aneu
Kaplan-Meier curves for cardiac event-free survival in KD patients with initial aneurysmal
medium aneurysm ¼ 4 to 6 mm>; small aneurysm ¼ <4 mm (log-rank test, p ¼ 0.01coronary involvement alone will determine the fate of
coronary artery lesions, especially in KD patients with
intermediate to high risk (risk levels III and IV), because
assigned coronary risk level is not permanently ﬁxed for
given patients and may change over the course of follow-up.
Coronary stenosis provokes ischemia by DSE as a result
of its hemodynamic consequences on depressed coronary
ﬂow reserve. In general, the stenosis of epicardial coronaryrysmal Size
sizes divided as follows: giant aneurysm ¼ 8 mm; large aneurysm ¼ 6 to 8 mm;
2). AN ¼ aneurysm; KD ¼ Kawasaki disease.
Table 3 Univariate Predictors of MACEs
Variable RR 95% CI p Value
Giant AN (8 mm) 5.21 1.08–25.06 0.039
Positive DSE 8.87 1.16–67.70 0.035
Large to giant AN (6 mm) 3.15 1.09–9.18 0.021
% Stenosis (LCA) 1.01 0.98–1.02 0.005
Grade of WMSI at peak stress (1–5) 3.28 1.73–6.20 <0.001
AN ¼ aneurysm; CI ¼ conﬁdence interval; DSE ¼ dobutamine stress echocardiography; LCA ¼ left
coronary artery; MACE ¼ major adverse cardiac event(s); RR ¼ relative risk; WMSI ¼ wall motion
score index.
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343arteries can be either ﬁxed or dynamic (18). In this study,
myocardial ischemia induced by DSE was detected in KD
patients with signiﬁcant CAD. Moreover, myocardial
ischemia was also detected in those with giant aneurysm
without signiﬁcant CAD, in which blood ﬂow is sluggish
and risk for thrombosis is high, suggesting the inﬂuence of
dynamic coronary stenosis superimposed on any degree of
anatomical ﬁxed stenosis (19). However, the mechanism
causing myocardial ischemia by DSE remains elusive
because of its unpredictable nature. Other possible causes of
myocardial ischemia in KD patients with giant aneurysm
without signiﬁcant CAD may be related to the microvas-
cular changes after systemic vasculitis due to KD causing
reduced coronary ﬂow reserve (20). Inevitably, CAG eval-
uates the anatomic component of myocardial ischemia by
means of purely morphologic, static evaluation of the coro-
nary tree. In contrast, DSE can induce ischemia through
hemodynamic consequences in coronary ﬂow reserve that are
totally different from static evaluations such as CAG.
Consequently, the 2 parameters (the anatomic and patho-
physiologic) can occasionally diverge with CALs without
signiﬁcant CAD and markedly depressed coronary ﬂow
reserve. Our study demonstrated that functional and organic
coronary stenosis was associated with a variable extent over
time in the individual KD patients with CALs. Therefore,
DSE may have potential to be a powerful tool for assessing
the functional signiﬁcance of CALs that are responsible for
latent vulnerability of myocardial ischemia and especially in
predicting future cardiac events over time in patients with
KD and CALs.
Study limitations. Several limitations might have inﬂu-
enced the results of this study. First, it is clear that the
diagnostic accuracy of any test varies according to the pre-test
likelihood of CAD in the population tested (21). The pre-
test likelihood of our KD patients with CAD may be
higher than that expected because of the tertiary referral bias.
This is a potential limitation of this study. Second, the often
quoted limitations of DSE are suboptimal image quality and
lack of quantitation (22). However, suboptimal images
observed in this study were rare, mainly due to the recent
advances in harmonic imaging and digital imaging and
display technology, as well as better imaging windows ob-
tained from adolescents and young adults with KD than
those from older adults. It has been shown convincingly inlarge multicenter trials that the newer modes of imaging,
including harmonic and contrast imaging, have not only
improved image quality but also have provided reproducible
image interpretation (23). Moreover, recent development in
two-dimensional speckled tracking imaging during DSE
may enable better quantiﬁcation for identifying ischemic
regions (24). Third, we applied both quantitative CAG
and CTCA as the reference standard for comparison of
the results of DSE. Although the heavy calcium burden on
post-KD coronary arteries could overestimate the degree of
coronary stenosis, the current study demonstrated almost
identical diagnostic accuracy for the detection of CAD
between the two techniques upon setting the same threshold
of coronary stenosis (25). Fourth, we did not focus on the
intercoronary collateral circulation detected by CAG or
CTCA that may protect against myocardial ischemia during
follow-up in patients with KD and CALs in this study.
Finally, due to the small number of KD patients with
MACEs in this study, the results from multivariate models
do not provide an applicable predictive power for future
MACEs. These results should thus be interpretedwith caution.
Clinical implications. The present study has important
clinical implications. Although the existence of large to giant
aneurysms at (I) alone may enhance the risk level of
MACEs, the higher WMSI (1.25, e.g., over 2 segments
with akinesia induced by DSE) in KD patients identiﬁed
a subset of patients at higher risk of MACEs. For these
patients, an aggressive approach must be undertaken
according to American Heart Association guidelines to
prevent MACEs during follow-up (11). In contrast, the
incidence of MACEs in KD patients with a negative DSE
or lower WMSI (<1.25) is so low that no additional
intervention could be indicated. Furthermore, one distinct
advantage of DSE for assessment of CALs is to minimize
the radiation exposure to this population. Indeed, the
effective dose for single myocardial perfusion imaging ranges
from ¡10 mSv for standard rest-stress protocols using
99mTc sestamibi or tetrofosmin, and the effective dose for
CTCA is comparable to that of myocardial perfusion
imaging. Moreover, the effective dose for conventional
diagnostic CAG varies from 2.3 to 22.7 mSv depending on
numerous factors. Coronary, peripheral, and electrophysio-
logical interventional procedures may deliver radiation doses
3 to 5 times this level (26). Therefore, in an integrated risk-
beneﬁt balance, DSE has shown advantage when compared
with other imaging modalities.
Conclusions
In this study, DSE demonstrated high feasibility in the risk
stratiﬁcation of KD patients with CALs. Moreover, DSE
showed the possibility of being a powerful tool for assessing
the functional signiﬁcance of CALs for predicting future
MACEs in KD patients with CALs who had coronary
aneurysms with marked morphological diversity during
follow-up. Future investigation of the prognostic impact of
Noto et al. JACC Vol. 63, No. 4, 2014
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344DSE in adult KD patients with CALs in greater detail is
warranted.
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